Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17965203 | 0.87 | S1PR1 (0.49) | S1PR1S1PR3SMN1; SMN2 | |
| SCHEMBL14242790 | 0.85 | GPR119 (0.47) | CETPGPR119PIK3CASMN1; SMN2 | |
| SCHEMBL14242828 | 0.84 | P2RY14 (0.55) | CETPGPR119S1PR1S1PR3JAK2 | |
| SCHEMBL17965196 | 0.81 | S1PR1 (0.45) | S1PR1S1PR3 | |
| SCHEMBL14243229 | 0.79 | PIK3CA (0.56) | CETPGPR119PIK3CASMN1; SMN2P2RY14 | |
| SCHEMBL14157378 | 0.78 | GPR119 (0.62) | GPR119 | |
| SCHEMBL23411137 | 0.77 | GPR119 (0.48) | GPR119SMN1; SMN2 | |
| SCHEMBL29967084 | 0.77 | GPR119 (0.48) | GPR119SMN1; SMN2 | |
| SCHEMBL14157382 | 0.77 | GPR119 (0.48) | CETPGPR119PIK3CASMN1; SMN2 | |
| SCHEMBL14157394 | 0.77 | GPR119 (0.52) | CETPGPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | claimed |
| EP-2718279-B1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-10 | — | — | EP | claimed |
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-12-17 | — | — | US | claimed |
| US-9181214-B2 | Bicyclic compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-11-10 | — | — | US | claimed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | claimed |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-11-30 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9777018-B2 | Compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| EP-2718279-B1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-12-17 | — | — | US | disclosed |
| US-9181214-B2 | Bicyclic compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181214-B2 | Bicyclic compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9181214-B2 | Bicyclic compounds as modulators of GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | disclosed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | disclosed |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2013-02-21 | — | — | US | disclosed |
| WO-2012170867-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361092-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | CETP 897/4885GPR119 1/4885S1PR1 549/4885 |
| US-20130045986-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | CETP 897/4885GPR119 1/4885S1PR1 549/4885 |
| US-20170342089-A1 | NOVEL COMPOUNDS AS MODULATORS OF GPR-119 | GPR119, GPR39, GPBAR1 | CETP 897/4885GPR119 1/4885S1PR1 549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.